NSPR
InspireMD, Inc.
NASDAQ · Healthcare · Medical - Devices · IL
$0.86
+1.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.8M | 9.0M | 7.0M | 6.2M | 5.2M |
| Cost of Revenue | 8.9M | 6.3M | 5.5M | 4.4M | 4.1M |
| Gross Profit | 2.0M | 2.6M | 1.5M | 1.8M | 1.1M |
| Operating Expenses | |||||
| R&D Expense | 16.2M | 15.0M | 13.6M | 8.0M | 7.8M |
| SG&A Expense | 39.3M | 37.3M | 21.4M | 15.0M | 12.0M |
| General & Admin Expense | 19.3M | 20.7M | 15.3M | 11.1M | 8.4M |
| Selling & Marketing Expense | 20.0M | 16.6M | 6.1M | 3.9M | 3.7M |
| Other Expenses | — | (502.0K) | — | — | — |
| Total Operating Expenses | 55.5M | 51.8M | 35.0M | 22.9M | 19.8M |
| Cost and Expenses | 64.4M | 58.1M | 40.5M | 27.3M | 23.9M |
| Operating Income (EBIT) | (53.6M) | (49.1M) | (33.5M) | (21.1M) | (18.7M) |
| Non-Operating | |||||
| Interest Income | 850.0K | — | 1.6M | 1.3M | 250.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 850.0K | — | 1.6M | 1.3M | 250.0K |
| Other Non-Op Income/Expense | 15.1M | 389.0K | 1.6M | 1.3M | 250.0K |
| Non-Operating Income (excl Interest) | (15.1M) | (389.0K) | (1.6M) | (1.3M) | (250.0K) |
| EBT (Pre-Tax Income) | (38.4M) | (48.7M) | (31.9M) | (19.9M) | (18.5M) |
| Income Tax Expense | 63.0K | 63.0K | 59.0K | 65.0K | 28.0K |
| Bottom Line | |||||
| Net Income | (38.5M) | (48.8M) | (32.0M) | (19.9M) | (18.5M) |
| Earnings from Cont. Ops | (38.5M) | (48.8M) | (32.0M) | (19.9M) | (18.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (38.5M) | (48.8M) | (32.0M) | (19.9M) | (18.5M) |
| Per Share | |||||
| Basic EPS | ($0.50) | ($0.76) | ($0.76) | ($0.82) | ($2.35) |
| Diluted EPS | ($0.50) | ($0.76) | ($0.76) | ($0.82) | ($2.35) |
| Revenue Per Share | $0.15 | $0.12 | $0.17 | $0.26 | $0.66 |
| Shares | |||||
| Basic Shares Outstanding | 73.5M | 73.5M | 41.9M | 24.3M | 7.9M |
| Diluted Shares Outstanding | 73.5M | 73.5M | 41.9M | 24.3M | 7.9M |
| Profitability Metrics | |||||
| EBITDA | (37.9M) | (48.2M) | (31.7M) | (19.6M) | (18.3M) |
| D&A | 557.0K | 476.0K | 280.0K | 232.0K | 188.0K |
| EBIT | (38.4M) | (48.7M) | (31.9M) | (19.9M) | (18.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026